Prognostic Factors and Their Impact on Survival in Patients with De Novo Metastatic Breast Cancer

Basit Öğe Kaydı
dc.contributor.authorErdis, Eda
dc.contributor.authorYilmaz, Mukaddes
dc.contributor.authorUcar, Mahmut
dc.contributor.authorYucel, Birsen
dc.contributor.authorKaradayi, Kursat
dc.date.accessioned2025-05-04T16:45:36Z
dc.date.available2025-05-04T16:45:36Z
dc.date.issued2025
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractThis study aimed to investigate the prognostic factors affecting overall survival (OS) in patients with de novo metastatic breast cancer (dnMBC). Additionally, the importance of local treatments on survival was evaluated. The data of 106 patients with dnMBC were analyzed. Primary breast surgery was performed in 15 patients (14%), while first-line systemic therapy constituted the initial treatment modality for 91 patients (86%). Local treatments were administered to 48 patients (45%), of which 63% underwent breast surgery alone and 37% underwent both breast surgery and radiotherapy. In univariate analysis, patient performance status, extent of metastasis, response of primary breast tumors and metastatic lesions to first-line systemic therapy, administration of local treatments, and the use of breast radiotherapy and surgery were identified as prognostic factors (p< 0.050). In multivariate analysis, being in the triple-negative subgroup (HR: 5.06, 95% CI: 2.46-10.43, p< 0.001), having polymetastatic disease (HR: 1.19, 95% CI: 1.15-3.17, p= 0.013), partial response of metastatic lesions to first-line systemic therapy (HR: 2.25, 95% CI: 1.84-4.29, p= 0.014), and non-response to first-line systemic therapy (HR: 2.67, 95% CI: 1.56-4.59, p< 0.001) were identified as independent poor prognostic factors. The median OS was 34 months, with 2-year OS at 58% and 5-year OS at 19%. The most significant prognostic factors for dnMBC in this study were molecular subtyping, extent of metastasis, and response of metastatic lesions to first-line systemic therapy. Although local treatments targeting the breast influenced prognosis, their impact was not as strong as the aforementioned variables.
dc.identifier.doi10.4999/uhod.257970
dc.identifier.endpage50
dc.identifier.issn1306-133X
dc.identifier.issue1
dc.identifier.scopus2-s2.0-105003025992
dc.identifier.scopusqualityQ4
dc.identifier.startpage41
dc.identifier.urihttps://doi.org/10.4999/uhod.257970
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35137
dc.identifier.volume35
dc.identifier.wosWOS:001460653500005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherAkad Doktorlar Yayinevi
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250504
dc.subjectDe novo metastatic breast cancer
dc.subjectRadiotherapy
dc.subjectPrognostic factors
dc.subjectOverall survival
dc.titlePrognostic Factors and Their Impact on Survival in Patients with De Novo Metastatic Breast Cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu